spacer
home > ebr > spring 2018 > from pharma to beauty
PUBLICATIONS
European Biopharmaceutical Review

From Pharma to Beauty

We are surrounded by microbes: in the air we breathe, our environment, and our body itself, which harbours billions of microbes in our gut, skin, eyes, urinary tract, etc. They interact with the body’s main functions and particularly its natural defences. Back in the 1970s, doctors had the idea to use parts of microbes (bacterial lysates) to stimulate immune defences. These mixtures of inactivated pathogenic bacteria were able to protect the body by stimulating both types of immune response: acquired and innate. Today, as people are looking for holistic approaches to protect their health, bacterial lysates have gained renewed interest. Their modes of actions are better understood as they have the ability to stimulate the immune defences, but also to reduce inflammatory reactions when the immune system is overloaded. Thus, their scope of applications has grown and they can currently be used in various areas: as drugs for the prevention of respiratory infections, but also in dermo-cosmetic applications.

What Are Bacterial Lysates?

Bacterial lysates are mixtures of inactivated, killed bacteria that may contain all the components of the bacteria cells (soluble and insoluble). In drug applications, bacterial lysates may be derived from inactivated pathogenic bacteria; the principle is to trigger immune surveillance thanks to the antigens derived from the bacteria and to up-regulate immune defences to prevent and help fight infections. In other cases, such as certain cosmetic applications, the bacteria used may be commensal or bacteria selected from the environment.

In the case of immunostimulant drugs, polyvalent bacterial lysates are prepared from different species of bacteria. Each strain is grown independently in fermenters, harvested, then inactivated by heat, and lysed using either mechanical or chemical lysis. Chemical lysates are obtained by the action of chemical alkaline substances that may denature the antigenic structures. Mechanical bacterial lysates are obtained by high pressure, which preserves the particulate antigens. This is of importance as the preservation of the antigenic structure warrantees a stronger immune response. After lyophilisation, the different lysates are mixed in fixed proportions, and formulated into finished products (sub-lingual tablets, capsules, sachets, and so on).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
A specialist in microbiology and microbial applications, Dr Christian Sanchez has headed the specialty division of Lallemand group from 1983 to 2011, where he was instrumental in the development of the group activities in key markets such as oenology, animal and human nutrition, and pharma applications before supporting the recent development of the plant care division of the company. Today, as Senior Vice President and Special Advisor, he advises the company on new developments for microbial solutions, such as the cosmetics market. Christian holds a Doctorate in biological science from Toulouse University, France, and held various positions in teaching and research at Toulouse University before joining the biotechnology industry. 

Maxence de Villemeur is Marketing and Sales Manager for Lallemand Pharma since October 2010 and is in charge of global business and marketing development of polyvalent mechanical bacterial lysates. Prior to this, she was Product Manager in the health division of Lallemand. Maxence has over 15 years of marketing and business experience in international healthcare and pharma markets. She holds an MBA in international management from ESC Clermont-Ferrand, France, and graduated in product development engineering from Cergy-Pontoise Industrial Biology Engineering School at EBI, France.
spacer
Dr Christian Sanchez
spacer
spacer
spacer
Maxence de Villemeur
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement